Semaglutide vs Endothelin-1

Semaglutide and Endothelin-1 represent two poles of peptide research: one is a synthetic analog optimized for therapeutic stability and receptor activation, the other is a native signaling molecule with profound but transient physiological effects. Semaglutide, a long-acting GLP-1 receptor agonist, is supported by robust clinical evidence from the STEP and SUSTAIN trials, making it a gold standard in metabolic and cardiovascular research. In contrast, Endothelin-1 is not used therapeutically but serves as a critical tool for studying vasoconstriction, endothelial dysfunction, and pulmonary hypertension pathogenesis. Their research applications rarely overlap, and the choice between them depends on whether the experimental focus is metabolic regulation or vascular biology.

Semaglutide is a synthetic GLP-1 receptor agonist with 94% sequence homology to human GLP-1, designed for once-weekly subcutaneous administration. Its molecular formula (C187H291N45O59) and molecular weight (~4113.6 g/mol) reflect its peptide backbone with fatty acid side chain modifications that enable albumin binding and prolonged half-life. The mechanism involves activation of GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, leading to glucose-dependent insulin secretion, delayed gastric emptying, and appetite suppression. Evidence strength is exceptionally high: the SUSTAIN program (type 2 diabetes) and STEP program (obesity) collectively enrolled tens of thousands of participants, demonstrating significant weight loss (15% mean reduction in STEP 1), improved glycemic control (HbA1c reductions of 1.5–2.0%), and reduced major adverse cardiovascular events (14% risk reduction in SUSTAIN 6). FDA approval for type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), and non-cirrhotic MASH (2024) underscores its translational relevance. No generic versions exist, and the FDA has issued warnings about counterfeit products, emphasizing the need for sourcing integrity in research.

Endothelin-1 (ET-1) is a 21-amino-acid peptide (MW ~2491.9 g/mol) produced primarily by vascular endothelial cells. It is the most potent endogenous vasoconstrictor known, with effects lasting hours. While ET-1 itself is not used therapeutically, endothelin receptor antagonists (ERAs) such as bosentan, ambrisentan, and macitentan are FDA-approved for pulmonary arterial hypertension (PAH).

Key claims: ET-1 is the most potent endogenous vasoconstrictor; ET-1 pathway is central to pulmonary arterial hypertension pathogenesis; Endothelin receptor antagonists improve PAH outcomes.

Semaglutide and Endothelin-1 target fundamentally different research domains with minimal direct overlap. Semaglutide is central to studies of metabolic health, including weight management, insulin sensitivity, and energy homeostasis, as well as cardiovascular outcomes research and non-alcoholic steatohepatitis (MASH). Endothelin-1, conversely, is a cornerstone of vascular biology research, particularly for investigating pulmonary hypertension pathogenesis, systemic vasoconstriction, and endothelial dysfunction. A rare intersection occurs in cardiovascular biology: Semaglutide's cardiovascular benefits may involve endothelial function modulation, while ET-1 is a direct mediator of vascular tone. However, researchers should not expect interchangeable use; the selection depends on whether the experimental question addresses metabolic regulation (Semaglutide) or vascular pathophysiology (Endothelin-1).

Semaglutide's safety profile is well-characterized from large clinical trials. Common adverse events (≥5% incidence) include nausea, vomiting, diarrhea, abdominal pain, and constipation, which are typically dose-dependent and transient, often mitigating with gradual dose titration. Additional effects such as dyspepsia, eructation, flatulence, headache, dizziness, and fatigue are reported. Serious but rare events include pancreatitis (acute and chronic), gallbladder disease (cholelithiasis, cholecystitis), and severe allergic reactions (urticaria, angioedema, anaphylaxis). Thyroid C-cell tumors have been observed in rodent models, but clinical relevance in humans remains uncertain. In contrast, Endothelin-1 is not administered as an exogenous therapeutic agent; safety data derive from endogenous overproduction studies. Elevated ET-1 levels are implicated in pulmonary hypertension, heart failure, chronic kidney disease, and systemic hypertension. Experimental intravenous ET-1 infusion in animals causes marked vasoconstriction, hypertension, and reduced cardiac output, highlighting its potency as a research tool but also its potential for acute hemodynamic instability if mishandled in laboratory settings.